Stay updated with breaking news from Mnkd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MannKind Co. (NASDAQ:MNKD – Free Report) – Analysts at Wedbush issued their Q2 2024 earnings estimates for shares of MannKind in a research report issued to clients and investors on Wednesday, February 28th. Wedbush analyst A. Argyrides forecasts that the biopharmaceutical company will post earnings of $0.02 per share for the quarter. Wedbush currently has […] ....
MannKind Co. (NASDAQ:MNKD – Get Free Report) shares rose 10.6% during trading on Wednesday . The company traded as high as $4.26 and last traded at $4.18. Approximately 1,060,401 shares traded hands during trading, a decline of 56% from the average daily volume of 2,431,067 shares. The stock had previously closed at $3.78. Wall Street […] ....
C M Bidwell & Associates Ltd. bought a new position in shares of MannKind Co. (NASDAQ:MNKD – Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 25,685 shares of the biopharmaceutical company’s stock, valued at approximately $106,000. A […] ....
C M Bidwell & Associates Ltd. bought a new position in shares of MannKind Co. (NASDAQ:MNKD – Free Report) in the third quarter, according to the company in its most recent filing with the SEC. The fund bought 25,685 shares of the biopharmaceutical company’s stock, valued at approximately $106,000. Other institutional investors have also modified […] ....
By Colin Kellaher MannKind has sold a 1% royalty interest in sales of the lung-disease treatment Tyvaso DPI to asset manager Sagard in a deal worth up to. ....